20 July 2017Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
26 April 2022   BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.

More on this story

Generics
26 April 2022   BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.

More on this story

Generics
26 April 2022   BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.